



23 **Research in context**

24 Evidence before this study

25 To map this field, bibliographic searches were conducted in the *Web of Science*, which included  
26 the following results: (i) COVID-19 (95,133 hits), (ii) SARS COV-2 (33,680 hits), (iii) testing  
27 policy and COVID-19 (939 hits), (iv) testing policy and SARS COV-2 (340 hits), (v) testing  
28 policy and COVID-19 and asymptomatic (80 hits), (vi) testing policy and SARS COV-2 and  
29 asymptomatic (54 hits); (vii) test positivity and COVID-19 and validation (7 hits), and (viii) test  
30 positivity and SARS CoV-2 and validation (5 hits). Therefore, before this study, testing policy in  
31 relation to asymptomatic cases as well as test positivity represented a very low proportion  
32 (between ~1 thousandth to ~ 1 ten thousandth) of all publications. While many articles  
33 distinguished between diagnostic and screening tests, no paper was found in which testing policy  
34 is mentioned as part of a process ultimately designed to isolate all infected individuals. The few  
35 articles that mentioned test positivity only investigated symptomatic cases. These  
36 quanti/qualitative assessments led the authors to infer that neither testing policy nor test  
37 positivity had been adequately validated and/or investigated.

38

39 Added value of this study

40 We provide the first validation of test positivity as an estimate of disease prevalence under  
41 rapidly changing conditions: in pandemics, disease prevalence may vary markedly within short  
42 periods of time. We also address a double limitation of control campaigns against COVID-19,  
43 namely: it is unknown *who* and *where* to test. Asymptomatic cases are not likely to seek medical  
44 assistance: while they feel well, they silently spread this pandemic. Because they represent  
45 approximately half of all infected individuals, they are a large, moving, and invisible target.

46 *Where* to find them is also unknown because (i) randomized testing is likely to fail and (ii)  
47 testing is very limited. Usually, the locations where infected people reside are not randomly  
48 distributed but geographically clustered, and, up to now less than four persons per thousand  
49 inhabitants are tested on a given day. However, by combining geo-referenced test positivity data  
50 with cost-benefit considerations, we generate approaches not only likely to induce high benefits  
51 without increasing costs but also free of assumptions: we measure bio-geography as it is.

52

### 53 Implications of all the available evidence

54 The fact that asymptomatic cases were not tested in many countries may explain the exponential  
55 growth and much higher number of deaths observed in those countries. Ineffective testing (and,  
56 therefore, ineffective isolation) can also result from the absence of geo-referenced data analysis.  
57 Because the geographical location where people reside, work, study, or shop is not a random  
58 event, the analysis of small geographical areas is essential. Only when actual geographical  
59 relationships are observed, optimal (cost-benefit oriented) testing policies can be devised.

60

61 **Summary**

62 **Background** To stop pandemics, such as COVID-19, infected individuals should be detected,  
63 treated if needed, and –to prevent contacts with susceptible individuals– isolated. Because most  
64 infected individuals may be asymptomatic, when testing misses such cases, epidemics may  
65 growth exponentially, inducing a high number of deaths. In contrast, a relatively low number of  
66 COVID-19 related deaths may occur when both symptomatic and asymptomatic cases are tested.

67 **Methods** To evaluate these hypotheses, a method composed of three elements was evaluated,  
68 which included: (i) county- and country-level geo-referenced data, (ii) cost-benefit related  
69 considerations, and (iii) temporal data on mortality or test positivity (TP). TP is the percentage of  
70 infections found among tested individuals. Temporal TP data were compared to the tests/case  
71 ratio (T/C ratio) as well as the number of tests performed/million inhabitants (tests/mi) and  
72 COVID-19 related deaths/million inhabitants (deaths/mi).

73 **Findings** Two temporal TP profiles were distinguished, which, early, displayed low (~ 1 %)   
74 and/or decreasing TP percentages or the opposite pattern, respectively. Countries that exhibited  
75 >10 TP % expressed at least ten times more COVID-19 related deaths/mi than low TP countries.  
76 An intermediate pattern was identified when the T/C ratio was explored. Geo-referenced, TP-  
77 based analysis discovered municipalities where selective testing would be more cost-effective  
78 than alternatives.

79 **Interpretations** When TP is low and/or the T/C ratio is high, testing detects asymptomatic  
80 cases and the number of COVID-19 related deaths/mi is low. Geo-referenced TP data can  
81 support cost-effective, site-specific policies. TP promotes the prompt cessation of epidemics and  
82 fosters science-based testing policies.

83 **Funding** None

## 84 **Introduction**

85           Albert Bartlett partially dedicated his life to teaching the expressions and consequences  
86 of the exponential function [1]. Epidemics –including the COVID-19 pandemic– tend to grow or  
87 decline exponentially. Given the catastrophic consequences of the epidemic exponential growth  
88 [2 Rudan ], the first priority in epidemic control is to avoid contacts: when it takes just 60 days to  
89 increase from 1 to > 60,000 COVID-19 related deaths (as observed in this pandemic),  
90 ‘coexistence with the virus’ or ‘flattening the epidemic curve’ is not a likely outcome.

91           Because blocking contacts between infected and susceptible individuals prevents the  
92 exponential growth of an epidemic, testing is the first priority of a control policy: it allows to  
93 detect, treat if needed, and isolate all infected individuals. Hence, the WHO summarizes its  
94 recommendations with three words: *test, treat, isolate* [3].

95           However, a substantial proportion of individuals infected with SARS CoV-2 may be  
96 infectious even without symptoms. Hence, identifying asymptomatic cases is a crucial element in  
97 epidemic control: if they were rapidly identified and subsequently isolated, the virus could be  
98 removed from the environment and the pandemic would stop [4-7]. The theoretical solution for  
99 this problem is to test every inhabitant of every country.

100           Unfortunately, massive testing (the type required to identify all infected individuals) is  
101 not currently feasible in most countries. This situation creates a new challenge: how can major  
102 disseminators of the COVID-19 pandemic be identified when testing is limited (or very limited)?

103           Therefore, a fourth action should be added to the three proposed by WHO: *identification*.  
104 The determination of the geographical sites where asymptomatic cases are likely to be located is  
105 the linchpin of epidemic control. However, only a minor proportion of the population is tested on  
106 a given day (usually less than four per thousand inhabitants [8]). Given the scarce resources

107 available, the limited testing, and the need to remove viral spreaders before the epidemic  
108 exponential growth overwhelms the anti-epidemic responses, identification should be precise,  
109 rapidly implemented, and cost-effective [9-11]. To address this composite problem, new metrics  
110 and methods may be required.

111 Test positivity (TP) is a concept to be considered. TP is the percentage of infections  
112 detected among tested individuals. While TP has been used for more than seven decades, in the  
113 context of COVID-19 it was first mentioned on March 30, 2020, by WHO [12]. Classically, TP  
114 has been utilized in reference to the ability of a test to identify and distinguish infection-positive  
115 from infection-negative individuals (also known as sensitivity and specificity, when the inference  
116 refers to the past; or test positive/negative predictive value, when the inference refers to the  
117 future). Such tests have a *diagnostic* purpose. They differ from *screening* tests [7, 13].

118 In this report, TP is viewed as a metric that may evaluate the efficacy of *testing programs*  
119 aimed at detecting asymptomatic COVID-19 cases; i.e., test positivity percentages may indirectly  
120 help to elucidate whether testing is or is not capturing asymptomatic cases, even when the  
121 number of tests performed per million inhabitants is low. In this context, TP is a component of  
122 an *epidemiologic* strategy used in a rapidly changing environment with the purpose of detecting  
123 and isolating infected individuals before the epidemic exponential process consolidates.

124 To the best of our knowledge, the validity of the TP metric to detect asymptomatic cases  
125 when testing is limited has not yet been demonstrated. To understand why TP percentages may  
126 achieve that goal, the history of epidemics is worth revisiting. When disease prevalence is zero  
127 (before an epidemic starts), the TP % is zero, too. The TP % is expected to be non-zero (but  
128 relatively low) after epidemic onset. That is so because even the worst epidemics on record have  
129 infected only a minor percentage of the population –for instance, the highest estimates on

130 fatalities induced by the 1918 flu pandemic are about 5% [14].

131           Accordingly, when the TP % approaches or exceeds 50% (as reported in several countries  
132 affected by COVID-19), it is unlikely that such numbers reflect the actual disease prevalence.  
133 Instead, high TP percentages may express testing conducted within a subpopulation that does not  
134 (or only marginally) promote(s) epidemic spread: the group of *symptomatic* cases. Because  
135 symptomatic cases are easily detected, they are also easily treated and isolated. Consequently,  
136 symptomatic cases are not likely to disseminate epidemics. In contrast, infected but undetected  
137 individuals –asymptomatic cases– transmit the disease [15].

138           Therefore, *high TP* percentages may be observed when the testing policy predominantly  
139 detects *symptomatic* cases (as explicitly pursued by official policies or promoted by research  
140 institutions of some countries [16-18]). This hypothesis is further supported when the alternative  
141 is associated with promising outcomes, that is, when lower TP values are found in countries  
142 where the testing policy explicitly captures asymptomatic cases and, later, much fewer deaths per  
143 million inhabitants are reported than in countries reporting high TP percentages. This means that  
144 low TP percentages may reflect the prompt removal of SARS CoV-2-positive individuals –a  
145 likely outcome of policies that test asymptomatic cases. Thus, empirically elucidating whether  
146 high TP percentages are found when asymptomatic cases are excluded in the testing policy as  
147 well as the alternative hypothesis –low TP percentages are associated with testing programs  
148 that detect asymptomatic cases– are pre-requisites of scientifically sound testing policies meant  
149 to identify and isolate the spreaders of epidemics.

150           Other metrics of potential interest include: (i) the number of new cases, (ii) the number  
151 of COVID-19 related deaths/million inhabitants (deaths/mi), and (iii) the ratio between the  
152 number of tests and the number of cases detected (the T/C ratio). The time when the highest

153 number of new cases occur is a relevant input of epidemiologic decision-making [19]. Because  
154 testing policies that only emphasize symptomatic cases will generate biased estimates on when  
155 new cases peak, approaches that detect asymptomatic cases are needed [16].

156 To demonstrate that novel testing methods can capture asymptomatic cases even when  
157 testing is limited, high-resolution, geo-referenced data may be required. When small  
158 geographical areas report high TP percentages, intensive testing in such areas could induce  
159 benefits that will include the larger surrounding area, generating high benefit-cost ratios [20].

160 Accordingly, relationships between the TP percentage, its inverse (the number of tests  
161 conducted per each detected case ratio or T/C ratio), and other metrics (the number of new cases  
162 and the number of deaths per million inhabitants) were investigated across countries and –using  
163 geo-referenced data of high resolution – across municipalities. This study aimed at elucidating  
164 whether, when and where the TP percentage and/or the T/C ratio informed earlier and/or  
165 provided more information than classic metrics in reference to asymptomatic cases and, if so  
166 demonstrated, whether such metrics, once geo-referenced, could foster region-specific, cost-  
167 benefit oriented control policies.

168

## 169 **Materials and methods**

### 170 Methods

171 Data on new (daily) tests performed, cases identified, test positivity (the percentage of positive  
172 cases/tests performed) and its inverse (the test/case ratio), as well as the cumulative number of  
173 tests or deaths per million inhabitants were collected from publicly available data sources and  
174 compared across countries and across time. Countries were classified as either displaying high or  
175 low test positivity (TP) when, at least three months after the initiation of the epidemic, they



176 showed non-overlapping intervals of TP and such classes also revealed non-overlapping intervals  
177 of epidemic-related outcomes (deaths/million inhabitants). Differences in median deaths/million  
178 inhabitants between low TP and high TP countries were investigated with the Mann-Whitney test  
179 using a commercial statistical package (Minitab LLC, State College, PA, USA). Geographical  
180 data were processed with ARC GIS software (ESRI, Redlands, Ca, USA). Thirteen countries  
181 were evaluated because, together, they exhibited geographical and demographic diversity and  
182 individually, they were affected by COVID-19 long enough (two or more months) so they could  
183 reveal exponential epidemic growth, if it happened. Such countries were: Bangladesh, Belgium,  
184 Colombia, Cyprus, Ethiopia, Germany, Greece, Italy, South Africa, South Korea, Spain,  
185 Uruguay, and the United States. To explore georeferenced data on test positivity, the  
186 municipality-specific data reported by Harvard University on Puerto Rico were analyzed  
187 [<https://rconnect.dfc.harvard.edu/covidpr/?s=08>]. Because many countries have reported errors  
188 and/or changed the definition of cases and deaths and because not all affected countries were  
189 investigated, inferences should not be construed to be representative. However, inferences  
190 derived from patterns observed in two or more countries (or regions of a country) may be viewed  
191 as plausible and, possibly, generalizable.

192

### 193 Data

194 Data were extracted from *Worldometer* and/or governmental sites (  
195 <https://www.worldometers.info/coronavirus/>; <https://www.pio.gov.cy/coronavirus/eng> ;  
196 <https://eody.gov.gr/epidimiologika-statistika-dedomena/ektheseis-covid-19/> ;  
197 <https://www.gub.uy/sistema-nacional-emergencias/>).

198

## 199 **Results**

### 200 Test positivity-related temporal patterns

201 Findings revealed two temporal patterns: (i) one characterized by an early TP peak (the  
202 highest TP percentages took place in the first weeks), followed by a rapid decline to ~ 1% (four  
203 countries, green rectangles, Figs. 1 A-D); and (ii) a pattern shared by six countries, which  
204 showed later and increasing TP values, even >10%, over one or more weeks (red rectangles,  
205 Figs. 1 E-J). In addition, the data of ten countries consistently demonstrated that the highest TP  
206 percentages occurred earlier or at the same time as, but not later than the number of new cases  
207 (Fig. 1 A-J). The first pattern (low TP percentage) was associated with a quasi-complete  
208 cessation of the epidemic within four months. The second pattern (high TP percentages) was  
209 shown by countries where, four to six months into the epidemic, the median number of deaths/mi  
210 was at least 10 times higher than in countries displaying the alternative pattern ( $p < 0.02$ , Fig. 2).

211

### 212 Validation of TP-based testing policies designed to detect asymptomatic cases

213 Four-dimensional (3D and temporal) plots that included TP percentages and T/C ratios  
214 identified three profiles, characterized by: (i) high TP percentages (data points shown only in the  
215 upper right quadrant, 4 countries); (ii) a hybrid pattern, which exhibited high TP and some high  
216 T/C observations (one country); and (iii) countries predominantly displaying high T/C ratio  
217 values (four countries, Figs. 3 A-I). TP values less than 5 % did not predict the end of the  
218 epidemic –even countries displaying < 1% TP over more than two weeks failed to report zero  
219 cases after such a period of time (Figs. 4 A-D).

220

### 221 Exploration of geo-referenced and temporal TP as tools of cost-effective policies

222 To investigate the hypothesis that geo-referenced and temporal TP data support site-  
223 specific, cost-effective interventions, the test positivity percentages reported in all municipalities  
224 of Puerto Rico on September 11, 2020, were investigated. One municipality reported a TP  
225 >50%, which was surrounded by 17 municipalities that reported much lower TPs. Assuming that  
226 testing resources (including tests) were distributed according to the size of the population, the  
227 municipality with >50% TP received 1/42 of such resources and the remaining municipalities  
228 obtained testing-related resources 42 times larger in magnitude (Fig. 5).

229 Such a situation facilitated cost-benefit oriented, geographically and epidemiologically  
230 specific interventions. For instance, if the level of testing implemented in area 1 (the  
231 municipality with >50% TP) was decided to be increased 1000%, immediately –but no new  
232 resources were provided–, the additional tests required in area 1 could only come from area 2.  
233 This means that 10 of the original 43 units of resources spent in areas 1 and 2 (1 unit spent in  
234 area 1 and 42 units spent in area 2) would now be used in area 1 (a 1000% increase). This  
235 solution would cause a 23.56 % reduction (from 42 to 32) in the units of resources spent in area 2  
236 – a region barely affected by the epidemic and, therefore, highly vulnerable (Fig. 5).

237 These data also estimated the costs of random testing and/or testing that ignores geo-  
238 temporal cost-benefit considerations. If the surrounding area (area 2) was affected as much as  
239 area 1, the size of epidemic could increase 42 times (Fig. 5). This epidemic growth could occur  
240 even if testing continued, uninterruptedly, at the same level as previously performed.

241

#### 242 Additional tools

243 Relationships between metrics elucidated when testing was or was not adequate.

244 Examples collected from 14 countries revealed when testing grew faster than cases (a desirable

245 outcome) or the alternative pattern suggested additional testing was needed (Fig. 6A-D). The use  
246 of the number of deaths per million inhabitants was also informative (Figs. 6 E-H).

247

## 248 **Discussion**

249 Because asymptomatic patients rarely request medical assistance, they may become the  
250 invisible spreaders of epidemics. Consequently, testing, treating, and isolating such cases should  
251 be prioritized [3]. However, given that testing is usually limited, their identification is  
252 problematic [8]. This compounded problem was addressed with an approach that, considering  
253 test positivity (TP), evaluated testing policies that prioritize the detection of asymptomatic cases  
254 and also considers geo-referenced, cost-benefit oriented data analysis.

255 Testing symptomatic or asymptomatic cases may depend on medical and public health-  
256 related perspectives [7]. For instance, testing that emphasizes symptomatic cases differs from  
257 screening-oriented testing. In the first case, it is assumed that epidemics can be stopped through  
258 interventions conducted within hospitals –as when individuals that feel ill seek medical  
259 assistance. It is expected to find high percentages of test positivity when *confirmatory* testing is  
260 promoted (the type of testing physicians are likely to prescribe). While this type of testing (or  
261 purpose) is necessary when a clinical perspective is considered, it does not contribute much to  
262 prevent epidemic spread, which depends on early detection of asymptomatic cases [7,18]. In  
263 contrast, in population medicine, *epidemiologic* testing is needed (screening or information  
264 usable in epidemic control, not only in clinical medicine). Here it was hypothesized that lower  
265 TP percentages predicted lower numbers of deaths per million inhabitants than when higher TP  
266 percentages were observed –findings consistent with the hypothesis that asymptomatic cases are  
267 detected when the percentage of TP is low. Findings supported these hypotheses, opening a path

268 toward scientifically grounded testing policies that seek to detect (and immediately isolate)  
269 asymptomatic –not only symptomatic– cases [7, 18]. As expected, countries that displayed high  
270 TP percentages in early epidemic stages, later reported many more deaths/mi than low TP  
271 countries. These findings supported the notion that, in high TP countries, asymptomatic cases  
272 were missed and, consequently, the epidemic grew exponentially and so did deaths.

273 The epidemics here investigated also showed that TP peaks occur earlier than the peak  
274 number of new cases. Data turning points (which include peaks) help to conduct epidemiologic  
275 forecasts [21].

276 Findings also addressed the statement made by WHO on May 12, 2020, which suggested  
277 that low (<5%) TP values over two consecutive weeks signal that an epidemic is under control  
278 [22]. This study found that even 1% TP was associated with longer epidemics (Figs. 3 A-D).

279 The fact that neither a 5% nor a 1 % TP cutoff predicted the immediate cessation of an  
280 epidemic was expected: dichotomization of continuous data promotes errors. Such a procedure  
281 assumes that the discrete (discontinuous) nature of a process can change below or above a cutoff  
282 generated by continuous data. Yet, the evidence demonstrated that an ‘epidemic-positive’  
283 country does not become an ‘epidemic-negative’ one when TP changes from 5.00 to 4.99 %.  
284 While pattern recognition can discriminate without numerical cutoffs (as Fig. 5 shows), the  
285 dichotomization assumption tends to lose information and generates errors [23].

286 Therefore, TP seems a robust and explanatory metric. Unlike the number of new cases,  
287 TP may inform *when* (and, provided that geo-referenced information is also available, *where*)  
288 spikes of its percentage will identify specific places that require additional testing so  
289 asymptomatic cases can be rapidly detected, isolated, and treated [24]. However, to prevent such  
290 patients from promoting exponential epidemic growth, early and geographically-specific

291 responses are needed. Here, an operational model showed that observable geo-epidemiologic  
292 features can generate site-specific, cost-effective interventions.

293 Investigating geo-referenced epidemiologic data matters because humans are not  
294 homogeneously distributed in space. Lakes, railroads, schools and many other (geographically  
295 specific) entities both separate and connect humans. While some geographical points act as  
296 epidemic nodes, many points do not seem to influence epidemic spread [25].

297 While earlier studies have conducted cost-benefit analysis of COVID-19 control policies,  
298 they lacked geo-referenced data [26]. The geo-referenced, cost-benefit theory followed in this  
299 study assumed that epidemics disseminate as floods do: from a ‘higher’ point (where disease  
300 prevalence or its surrogate, test positivity, is higher) toward surrounding areas where test  
301 positivity percentages are lower. When cost-benefit oriented interventions are not immediately  
302 implemented in such situations, the epidemiologic condition of the surrounding region can  
303 rapidly worsen. This epidemiologic ‘flood’ metaphor was empirically supported: rapid  
304 interventions in small areas that threaten larger areas tend to be highly cost-effective and may  
305 stop epidemics (Fig. 4).

306 While aggregate (state- or country- level) data do not reveal spatial relationships and,  
307 therefore, are not very useful [27], non-aggregate geo-referenced information –e.g., data on  
308 neighborhoods– are epidemiologically usable, as shown with municipality-level information  
309 collected in Puerto Rico (Fig. 5). When geographical-epidemiological relationships are  
310 considered, it is possible to identify policies that benefit not only the area of direct intervention  
311 but also the surrounding area –as commonly practiced in flood protection-related policies [28].  
312 This approach has also been described as the ‘wrong pocket problem’, i.e., the area where the  
313 investment is made does not only benefit from it: a larger area is benefited as well [29]. One

314 example of this geographically grounded, cost-benefit oriented approach has recently been  
315 applied in an emergency vaccination against rabies conducted in Tanzania, where a limited  
316 intervention in a small ring that surrounded a large city also benefitted the large city [11].

317 Findings support the view that, to stop epidemic exponential growth, testing policies should  
318 aim at detecting all infected individuals (including asymptomatic cases). In spite of its relevance,  
319 testing policy seems an area that lacks interdisciplinary scientific expertise. Approaches that  
320 include temporal and geo-referenced test positivity data, as well as cost-benefit oriented  
321 considerations, may contribute toward filling that gap.

322

### 323 **Contributors**

324 All authors contributed to model design, interpretation of results, and writing of the report. ALR,  
325 ALH, AI, AA and PV collected data. JBH and FOF transcribed and analyzed the data. JLF made  
326 maps, ALR and MHVvR drafted the manuscript.

327

### 328 **Declaration of interests**

329 We declare no competing interests.

330

### 331 **Data sharing**

332 No primary data were collected for this study, which used publicly available data. The sources of  
333 the data used are described in this article.

334

### 335 **Funding**

336 No funding was received from any agency in the commercial or non-profit sectors.

337

## 338 **References**

- 339 1. Arithmetic, Population and Energy - a talk by Al Bartlett.  
340 [https://www.albartlett.org/presentations/arithmetric\\_population\\_energy\\_video1.html](https://www.albartlett.org/presentations/arithmetric_population_energy_video1.html)  
341 [\(accessed Dec 5, 2020\)](#)
- 342 2. Rudan I. A cascade of causes that led to the COVID-19 tragedy in Italy and in other  
343 European Union countries. *J Glob Health* 2020; **10**: 010335.  
344 <https://doi.org/10.7189/jogh.10.010335>
- 345 3. World Health Organization. WHO coronavirus briefing: Isolation, testing and tracing  
346 comprise the 'backbone' of response. [https://www.weforum.org/agenda/2020/03/testing-](https://www.weforum.org/agenda/2020/03/testing-tracing-backbone-who-coronavirus-wednesdays-briefing/)  
347 [tracing-backbone-who-coronavirus-wednesdays-briefing/](#) (accessed Dec 5, 2020)
- 348 4. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based  
349 mitigation measures influence the course of the COVID-19 epidemic? *Lancet* 2020; **395**:  
350 931–934. [https://doi.org/10.1016/S0140-6736\(20\)30567-5](https://doi.org/10.1016/S0140-6736(20)30567-5)
- 351 5. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles' Heel of  
352 current strategies to control COVID-19. *N Engl J Med* 2020; **382**: 2158–2160.  
353 <https://doi.org/10.1056/NEJMe2009758>.
- 354 6. Han MS, Choi EH, Chang SH, et al. Clinical characteristics and viral RNA detection in  
355 children with coronavirus disease 2019 in the Republic of Korea. *JAMA Pediatr* 2020;  
356 Published online August 21. <https://doi.org/10.1001/jamapediatrics.2020.3988>
- 357 7. Raffle AE, Pollock AM, Harding-Edgar L. Covid-19 mass testing programmes. *BMJ* 2020;  
358 **370**: m3262. <http://dx.doi.org/10.1136/bmj.m3262>
- 359 8. Ourworldindata. Coronavirus (COVID-19) Testing. [https://ourworldindata.org/coronavirus-](https://ourworldindata.org/coronavirus-testing)  
360 [testing](#) (accessed Oct 28, 2020)



- 361 9. Rivas AL, [Tennenbaum](#) SE, [Aparicio](#) JP, et al. Critical response time (time available to  
362 implement effective measures for epidemic control): model building and evaluation. *Can J*  
363 *Vet Res* 2003; **67**: 307–311.
- 364 10. Rivas AL, Fasina FO, Hoogesteyn AL, et al. Connecting network properties of rapidly  
365 disseminating epizoonotics. *PLoS One* 2012; **7**: e39778.  
366 <https://doi.org/10.1371/journal.pone.00397782012>
- 367 11. Fasina FO, Mtui-Malamsha N, Mahiti GR, et al. Where and when to vaccinate?  
368 Interdisciplinary design and evaluation of the 2018 Tanzanian anti-rabies campaign. *IJID*  
369 2020; **95**: 352–360. <https://doi.org/10.1016/j.ijid.2020.03.037>
- 370 12. World Health Organization. COVID-19-virtual press conference -30 March 2020.  
371 [https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2)  
372 [coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a\\_2](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2) (accessed July 20,  
373 2020).
- 374 13. Speechley M, Kunnilathu A, Aluckal E, et al. Screening in Public Health and Clinical Care:  
375 similarities and differences in definitions, types, and aims – a systematic review. *J Clin Diagnostic*  
376 *Res* 2017; **11**: LE01–LE04.  
377 <https://doi.org/10.7860/JCDR/2017/24811.9419>
- 378 14. Roser M. The Spanish flu (1918-20): The global impact of the largest influenza pandemic in  
379 history. <https://ourworldindata.org/spanish-flu-largest-influenza-pandemic-in-history>  
380 (accessed Sept 24, 2020).
- 381 15. Basnarkov L. SEAIR epidemic spreading model of COVID-19. arXiv:2005.11815v2  
382 [physics.soc-ph] <http://arxiv.org/abs/2005.11815v2>
- 383 16. Iosa M, Paolucci S, Morone G. Covid-19: A dynamic analysis of fatality risk in Italy. *Front.*

- 384 *Med.* 2020, **7**: 185. <https://doi.org/10.3389/fmed.2020.00185>
- 385 17. Deutsche Welle. Germany's coronavirus response: Separating fact from fiction.
- 386 [https://www.dw.com/en/germanys-coronavirus-response-separating-fact-from-fiction/a-](https://www.dw.com/en/germanys-coronavirus-response-separating-fact-from-fiction/a-53053822)
- 387 [53053822](https://www.dw.com/en/germanys-coronavirus-response-separating-fact-from-fiction/a-53053822) (accessed Dec 5, 2020).
- 388 18. Padula WV. Why only test symptomatic patients? Consider random screening for
- 389 COVID-19. *Appl Health Econ Health Policy* 2020; **18**: 333–334.
- 390 <https://doi.org/10.1007/s40258-020-00579-4>
- 391 19. Tsallis C, Tirnakli U. Predicting COVID-19 peaks around the world. *Front Phys* 2020;
- 392 **8**: 217. <https://doi.org/10.3389/fphy.2020.00217>
- 393 20. Rivas AL, Hoogesteijn AL, Hittner JB, et al. Addressing a complicated problem: can
- 394 COVID-19 asymptomatic cases be detected – and epidemics stopped– when testing is limited
- 395 and the location of such cases unknown? medRxiv preprint
- 396 <https://doi.org/10.1101/2020.11.10.20223495>
- 397 21. Liu Z, Magal P, Webb G. Predicting the number of reported and unreported cases for the
- 398 COVID-19 epidemics in China, South Korea, Italy, France, Germany and United Kingdom.
- 399 medRxiv preprint doi: <https://doi.org/10.1101/2020.04.09.20058974>
- 400 22. World Health Organization. Considerations for implementing and adjusting public health and
- 401 social measures in the context of COVID-19. [https://www.who.int/publications/i/item/public-](https://www.who.int/publications/i/item/public-health-criteria-to-adjust-public-health-and-social-measures-in-the-context-of-covid-19)
- 402 [health-criteria-to-adjust-public-health-and-social-measures-in-the-context-of-covid-19](https://www.who.int/publications/i/item/public-health-criteria-to-adjust-public-health-and-social-measures-in-the-context-of-covid-19)
- 403 (accessed: Sept 4, 2020).
- 404 23. Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ* 2006; **332**:
- 405 1080. <https://doi.org/10.1136/bmj.332.7549.1080>
- 406 24. Machanick P. Revisiting early-stage COVID-19 strategy options [version 2; peer review:

- 407 awaiting peer review] *F1000 Research* 2020, 9:327.
- 408 <https://doi.org/10.12688/f1000research.23524.2>
- 409 25. Rivas AL, Febles JL, Smith SD, et al. 2020 Early network properties of the COVID-19  
410 pandemic – the Chinese scenario. *IJID* 2020; **96**: 519–523.
- 411 26. Reddy KP, Shebl KM, Foote JHA, et al. Cost-effectiveness of public health strategies for  
412 COVID-19 epidemic control in South Africa. *Lancet Glob Health* 2020; Nov 11:S2214-  
413 109X(20)30452-6. [https://doi.org/10.1016/S2214-109X\(20\)30452-6](https://doi.org/10.1016/S2214-109X(20)30452-6)
- 414 27. Ortiz-Pelaez A, Pfeiffer DU, Soares-Magalhães RJ, Guitian FJ. Use of social network  
415 analysis to characterize the pattern of animal movements in the initial phases of the 2001 foot  
416 and mouth disease (FMD) epidemic in the UK. *Prev Vet Med* 2006; **76**: 40–55.  
417 <https://doi.org/10.1016/j.prevetmed.2006.04.007>
- 418 28. Syrbe R-U, Walz U. Spatial indicators for the assessment of ecosystem services: Providing,  
419 benefiting and connecting areas and landscape metrics. *Ecol Indic* 2012; **21**: 80–88.  
420 <https://doi.org/10.1016/j.ecolind.2012.02.013>
- 421 29. McCullough JM. Declines in spending despite positive returns on investment: understanding  
422 Public Health’s Wrong Pocket Problem. *Front Public Health* 2019; **7**: 159.  
423 <https://doi.org/10.3389/fpubh.2019.00159>
- 424

425 **Figure legends**

426 **Fig. 1. Temporal relationships between the test positivity percentage and the number of**

427 **new cases.** Two epidemic patterns were differentiated among 10 countries: (i) epidemics that  
428 revealed a rapid decrease in the test positivity (TP) percentage and, subsequently, displayed very  
429 low (<1%) TP values (green rectangles, **A-D**); and (ii) epidemics that reported either later TP  
430 peaks, increasing percentages of the TP over two or more weeks, and/or TP percentages higher  
431 than 5% (red rectangles, **E-J**). In all ten countries investigated, the peak TP percentage occurred  
432 earlier than the peak number of new cases. Source: *Worldometer*.

433

434 **Fig. 2. Temporal relationships between test positivity percentage and deaths per million**

435 **inhabitants.** By August 25, 2020 (at least four months into the epidemic), the group of countries  
436 that, earlier, reported high (three-digit) test positivity percentages (high TP) showed at least 10  
437 times more deaths per million inhabitants (d/mi) than countries that, earlier displayed low (two-  
438 digit) TP percentages ( $p < 0.02$ , Mann-Whitney test). High and low TP countries revealed non-  
439 overlapping data intervals (rectangles). Source: *Worldometer*.

440

441 **Fig. 3. Temporal relationships between test positivity and the tests/case ratio.** The

442 assessment of the tests/case ratio revealed more information when nine countries were  
443 investigated, which partially included the set reported in Fig. 1. Four countries showed high TP  
444 percentages but few or no high tests/case ratios (**A-D**). One country displayed a hybrid pattern,  
445 which was characterized by a few high TP percentages and a few high tests/case ratios (**E**). The  
446 remaining four countries predominantly exhibited high tests/case ratios (**F-I**).

447

448 **Fig. 4. Pattern- vs. threshold-based evaluations of epidemic control measures.** Four

449 countries located in three continents showed new cases even when the percentage of test  
450 positivity (TP) was  $< 1\%$  (ovals, **A-D**). Because new cases were observed over protracted (more  
451 than two-week long) periods of time, it is concluded that no numerical cutoff (e.g.,  $TP < 5\%$ )  
452 indicates an epidemic is under control. In contrast, patterns –such as a perpendicular data  
453 inflection– promote inferences, regardless of any cutoff value.

454


455 **Fig. 5. Geo-epidemiologically specific, cost-benefit effective, differential testing.** The test  
456 positivity (TP) percentages reported in all municipalities of Puerto Rico, on Sept 11, 2020, are  
457 depicted. Area 1 shows the municipality of Jayuya. Area 2 identifies a larger, surrounding region  
458 that includes ~42 times more people and covers an area ~ 8.5 times larger than those of Jayuya.  
459 Given Jayuya +50% TP, a greater testing effort conducted in this municipality may yield large  
460 benefits, which may also include the surrounding area (Area 2) and, indirectly, benefit the  
461 western half of the island. Vice versa, keeping the same level of testing performed before may  
462 lead to long-lasting, costly consequences: if the virus circulating within Jayuya reached the  
463 surrounding area and the prevalence of COVID-19 became similar to the one affecting Jayuya  
464 (which is estimated by test positivity), then a much larger number of people (up to 42 times  
465 larger) could become infected, who would reside in an area 8.5 times larger, i.e., control would  
466 then be much harder, longer and costlier.

467


468 **Fig. 6. Relationships between outcomes (non-fatal or fatal infections) and the number of**  
469 **tests/million inhabitants.** Testing policies may be adjusted based on patterns generated by  
470 cases (**A-D**) and fatalities (**E-H**). When testing grows slower than cases or deaths (when the  
471 curvature approaches a vertical pattern), testing is likely to be insufficient or inadequate.

472

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




474 **Fig. 1. Temporal relationships between the test positivity percentage and the number of**  
475 **new cases.** Two epidemic patterns were differentiated among 10 countries: (i) epidemics that  
476 revealed a rapid decrease in the test positivity (TP) percentage and, subsequently, displayed very  
477 low (<1%) TP values (green rectangles, **A-D**); and (ii) epidemics that reported either later TP  
478 peaks, increasing percentages of the TP over two or more weeks, and/or TP percentages higher  
479 than 5% (red rectangles, **E-J**). In all ten countries investigated, the peak TP percentage occurred  
480 earlier than the peak number of new cases. Source: *Worldometer*.  
481  
482



483  
484 **Fig. 2. Temporal relationships between test positivity percentage and deaths per million**  
485 **inhabitants.** By August 25, 2020 (at least four months into the epidemic), the group of countries  
486 that, earlier, reported high (three-digit) test positivity percentages (high TP) showed at least 10  
487 times more deaths per million inhabitants (d/mi) than countries that, earlier displayed low (two-  
488 digit) TP percentages ( $p < 0.02$ , Mann-Whitney test). High and low TP countries revealed non-  
489 overlapping data intervals (rectangles). Source: *Worldometer*.


490  
491






492  
493  
494  
495  
496  
497  
498  
499  
500

**Fig. 3. Temporal relationships between test positivity and the tests/case ratio.** The assessment of the tests/case ratio revealed more information when nine countries were investigated, which partially included the set reported in Fig. 1. Four countries showed high TP percentages but few or no high tests/case ratios (A-D). One country displayed a hybrid pattern, which was characterized by a few high TP percentages and a few high tests/case ratios (E). The remaining four countries predominantly exhibited high tests/case ratios (F-I).




501  
502 **Fig. 4. Pattern- vs. threshold-based evaluations of epidemic control measures.** Four  
503 countries located in three continents showed new cases even when the percentage of test  
504 positivity (TP) was  $< 1\%$  (ovals, **A-D**). Because new cases were observed over protracted (more  
505 than two-week long) periods of time, it is concluded that no numerical cutoff (e.g.,  $TP < 5\%$ )  
506 indicates an epidemic is under control. In contrast, patterns –such as a perpendicular data  
507 inflection– promote inferences, regardless of any cutoff value.  
508



509  
510











511 **Fig. 5. Geo-epidemiologically specific, cost-benefit effective, differential testing.** The test  
512 positivity (TP) percentages reported in all municipalities of Puerto Rico, on Sept 11, 2020, are  
513 depicted. Area 1 shows the municipality of Jayuya. Area 2 identifies a larger, surrounding region  
514 that includes ~42 times more people and covers an area ~ 8.5 times larger than those of Jayuya.  
515 Given Jayuya +50% TP, a greater testing effort conducted in this municipality may yield large  
516 benefits, which may also include the surrounding area (Area 2) and, indirectly, benefit the  
517 western half of the island. Vice versa, keeping the same level of testing performed before may  
518 lead to long-lasting, costly consequences: if the virus circulating within Jayuya reached the  
519 surrounding area and the prevalence of COVID-19 became similar to the one affecting Jayuya  
520 (which is estimated by test positivity), then a much larger number of people (up to 42 times  
521 larger) could become infected, who would reside in an area 8.5 times larger, i.e., control would  
522 then be much harder, longer and costlier.

523













524

525 **Fig. 6. Relationships between outcomes (non-fatal or fatal infections) and the number of**  
526 **tests/million inhabitants.** Testing policies may be adjusted based on patterns generated by  
527 cases (A-D) and fatalities (E-H). When testing grows slower than cases or deaths (when the  
528 curvature approaches a vertical pattern), testing is likely to be insufficient or inadequate.







Deaths/million inhabitants (August 25, 2020)







**A****CYPRUS****B****GREECE****D****S. KOREA****D****URUGUAY**




67°W


66°W


18°N

17°N

TP\_Sep11



 Area 1 = 117.4 km<sup>2</sup>  
Population 1 = 13,891

 Area 2 = 2,467.1 km<sup>2</sup>  
Population 2 = 589,463

